Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Research Letter
You have accessRestricted Access

Serum Metabolites and Cardiac Death in Patients on Hemodialysis

Jiun-Ruey Hu, Morgan E. Grams, Josef Coresh, Seungyoung Hwang, Csaba P. Kovesdy, Eliseo Guallar, Eugene P. Rhee and Tariq Shafi
CJASN May 2019, 14 (5) 747-749; DOI: https://doi.org/10.2215/CJN.12691018
Jiun-Ruey Hu
1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiun-Ruey Hu
Morgan E. Grams
2Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Morgan E. Grams
Josef Coresh
2Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seungyoung Hwang
2Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Csaba P. Kovesdy
3Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Csaba P. Kovesdy
Eliseo Guallar
2Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene P. Rhee
4Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tariq Shafi
2Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, Maryland;
5Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tariq Shafi
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • clinical epidemiology
  • hemodialysis
  • cardiovascular disease
  • mortality
  • metabolism
  • dialysis
  • Kidney Failure, Chronic

Cardiovascular death is the leading cause of mortality in patients undergoing hemodialysis. However, traditional risk factors, such as diabetes, hypertension, and other comorbidities, do not fully account for this excess risk. Uremic toxins, substances that accumulate in patients with kidney failure, may be responsible for accelerated cardiovascular disease. However, these uremic toxins remain largely undefined. The goal of our pilot study was to determine if an untargeted metabolomic approach could identify metabolites associated with cardiac death in patients on dialysis.

We designed a matched patient-control study (n=94) nested in the Hemodialysis study, a trial of dialysis dose and flux (1). We defined cases as patients who had cardiac death within 1 year of study enrollment and matched them 1:1 to controls, defined as patients who were alive at the end of year 1. Both cases and controls were patients without residual kidney function, and they were matched on age within 5 years, sex, race, diabetes, cardiac disease, and albumin within 0.25 g/dl. Predialysis serum samples frozen at −80°C from the 4-month follow-up visit were sent to Metabolon, Inc. (Durham, NC) for metabolite profiling. We used the standardized methods for data cleaning detailed previously (2). There were 1266 metabolites detected (847 named and 419 unnamed). After excluding unnamed metabolites (n=419), drugs (n=56), and metabolites with >80% missing across samples (n=14), 777 metabolites remained for analysis. We scaled all metabolites to a median of one and log2 transformed. We used logistic regression to assess the association between each metabolite and cardiac death, adjusting for the matching factors (age, sex, race, diabetes, cardiovascular disease, and albumin), Index of Coexistent Disease score, duration of prior dialysis, and systolic BP. Because this was a discovery study, we set the threshold for significance at P<0.005. In a complementary analysis, we explored associations using a false discovery rate threshold of 0.1.

The 94 participants had a mean age of 63 (±13) years old, 62% were women, 53% had diabetes, and 96% had cardiac disease. The participants had received an average of 4 years of hemodialysis before study enrollment. The untargeted metabolites had high correlation (rho range, 0.80–0.95) with previous targeted measurements of selected metabolites measured at the same time point. Figure 1 displays the results for the association between the 777 metabolites and cardiac death. Using the P<0.005 threshold, higher odds for cardiac death were noted with higher levels of several lipid metabolites (3-hydroxybutyrate, myristoylcarnitine, palmitoleoylcarnitine, 3-hydroxylaurate, and laurylcarnitine), an amino acid metabolite (2-hydroxybutyrate/2-hydroxyisobutyrate), and phosphate. Lower odds of cardiac death were noted with higher levels of a vitamin E metabolite (α-carboxyethyl hydrochroman glucuronide). None of the metabolites had significant associations using the false discovery rate threshold.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A metabolomic approach identifies potential metabolites associated with cardiac death in the Hemodialysis (HEMO) study. (A) Volcano plot and table depicting odds ratios and confidence intervals of the associations between individual metabolites (m=777) and cardiac death at 1 year in the HEMO Study (n=94). Each open circle represents a single metabolite plotted by its odds ratio (x axis) and P value (y axis). The y-axis horizontal line at 0.005 represents the P value threshold used in the primary analysis. Closed circles represent metabolites with potential associations. (B) Cardiac death–related metabolites are presented with superpathways, subpathways, adjusted odds ratios (aORs) with 95% confidence intervals (95% CIs), P values for association on logistic regression (Ps), and Human Metabolome Database (HMDB) identification. (C) Tukey boxplots of log2-transformed and median-scaled metabolite levels of each of the cardiac death–related metabolites in patients and controls. Boxes indicate 25th, 50th, and 75th percentiles of data, with whiskers indicating values within 1.5 times the interquartile range above and below the median. Metabolites are color coded by pathway, whereby red denotes amino acids, green denotes carbohydrates, brown denotes cofactors, purple denotes energy metabolites, blue denotes lipids, orange denotes nucleotides, pink denotes peptides, and yellow denotes nondrug xenobiotics. The HEMO study was a patient-control design. Logistic regression models were adjusted for age, sex, race, diabetes, cardiovascular disease, albumin, Index of Coexistent Disease score, duration of prior dialysis, and systolic BP. cont, control.

Although this study does not necessarily suggest causality, some of the observed associations implicate interesting metabolic pathways. Elevated ketone bodies, such as 3-hydroxybutyrate (also known as β-hydroxybutyrate), are well described in patients with heart failure and may reflect increased sympathetic nervous system activity (3). Elevated ketone body levels were associated with cardiovascular mortality in a recent report from a Japanese dialysis cohort (4). Elevated acylcarnitines could be an indicator of mitochondrial dysfunction and were associated with cardiovascular mortality in an incident United States dialysis cohort (5). The association between elevated phosphate and cardiovascular disease is well known. The protective effect seen with higher levels of vitamin E metabolites could reflect the potential antioxidant effect of vitamin E, or it could be a marker of better nutritional status. Randomized trials of vitamin E supplementation in patients undergoing dialysis have shown mixed results in reduction of cardiovascular events and mortality.

In summary, this hypothesis-generating study suggests the potential of metabolomics as a tool for uremic toxin discovery. Disrupted metabolic pathways in uremia may inform the science of uremic toxin discovery and the development of targeted therapies. Such discoveries can change the way that we treat kidney failure, a major goal of the KidneyX initiative.

Disclosures

Dr. Kovesdy reports personal fees from Amgen, personal fees from Sanofi-Aventis, personal fees from Fresenius Medical Care, personal fees from Keryx, grants from Shire, personal fees from Bayer, personal fees from Abbott, personal fees from Abbvie, personal fees from Dr. Schar, personal fees from GSK, personal fees from Astra Zeneca, personal fees from Takeda, outside the submitted work.

Dr. Shafi reports personal fees from Siemens, personal fees from University of California Irvine, personal fees from University of Mississippi Medical Center, personal fees from Hershey Medical Center, personal fees from University of Tennessee, outside the submitted work.

Dr. Coresh, Dr. Grams, Dr. Guallar, Dr. Hu, Mr. Hwang, and Dr. Rhee have nothing to disclose.

Acknowledgments

Dr. Coresh reports grants from NIH, grants from NKF, during the conduct of the study.

Dr. Guallar reports grants from NIH/NHLBI (CAMARO-ESRD: Cardiac Arrhythmia Monitoring and Related Outcomes in End Stage Renal Disease, R01HL132372), during the conduct of the study.

Dr. Shafi reports grants from NIDDK, during the conduct of the study.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received October 25, 2018.
  • Accepted March 15, 2019.
  • Copyright © 2019 by the American Society of Nephrology

References

  1. ↵
    1. Greene T,
    2. Beck GJ,
    3. Gassman JJ,
    4. Gotch FA,
    5. Kusek JW,
    6. Levey AS,
    7. Levin NW,
    8. Schulman G,
    9. Eknoyan G
    : Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials 21: 502–525, 2000pmid:11018567
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hu J-R,
    2. Coresh J,
    3. Inker LA,
    4. Levey AS,
    5. Zheng Z,
    6. Rebholz CM,
    7. Tin A,
    8. Appel LJ,
    9. Chen J,
    10. Sarnak MJ,
    11. Grams ME
    : Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney Int 94: 381–389, 2018pmid:29871777
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lommi J,
    2. Kupari M,
    3. Koskinen P,
    4. Näveri H,
    5. Leinonen H,
    6. Pulkki K,
    7. Härkönen M
    : Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 28: 665–672, 1996pmid:8772754
    OpenUrlFREE Full Text
  4. ↵
    1. Obokata M,
    2. Negishi K,
    3. Sunaga H,
    4. Ishida H,
    5. Ito K,
    6. Ogawa T,
    7. Iso T,
    8. Ando Y,
    9. Kurabayashi M
    : Association between circulating ketone bodies and worse outcomes in hemodialysis patients. J Am Heart Assoc 6: pii:e006885, 2017pmid:28974498
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Kalim S,
    2. Clish CB,
    3. Wenger J,
    4. Elmariah S,
    5. Yeh RW,
    6. Deferio JJ,
    7. Pierce K,
    8. Deik A,
    9. Gerszten RE,
    10. Thadhani R,
    11. Rhee EP
    : A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc 2: e000542, 2013pmid:24308938
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 14 (5)
Clinical Journal of the American Society of Nephrology
Vol. 14, Issue 5
May 07, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Serum Metabolites and Cardiac Death in Patients on Hemodialysis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Serum Metabolites and Cardiac Death in Patients on Hemodialysis
Jiun-Ruey Hu, Morgan E. Grams, Josef Coresh, Seungyoung Hwang, Csaba P. Kovesdy, Eliseo Guallar, Eugene P. Rhee, Tariq Shafi
CJASN May 2019, 14 (5) 747-749; DOI: 10.2215/CJN.12691018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Serum Metabolites and Cardiac Death in Patients on Hemodialysis
Jiun-Ruey Hu, Morgan E. Grams, Josef Coresh, Seungyoung Hwang, Csaba P. Kovesdy, Eliseo Guallar, Eugene P. Rhee, Tariq Shafi
CJASN May 2019, 14 (5) 747-749; DOI: 10.2215/CJN.12691018
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis
  • Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum
  • Implementation of a Staff-Assisted Peritoneal Dialysis Program in the United States
Show more Research Letter

Cited By...

  • Identification of Novel Biomarkers and Pathways for Coronary Artery Calcification in Nondiabetic Patients on Hemodialysis Using Metabolomic Profiling
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • clinical epidemiology
  • hemodialysis
  • cardiovascular disease
  • mortality
  • metabolism
  • dialysis
  • Kidney Failure, Chronic

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire